GLP-1 Resource Center

What is the difference between Ozempic and Wegovy?

Ozempic and Wegovy contain the same active ingredient, semaglutide, but they are different products approved for different purposes at different doses. Understanding the distinction clarifies what you are taking and why the nutritional consequences are similar regardless of which you are prescribed.

The same molecule, different doses

Both Ozempic and Wegovy are injectable semaglutide manufactured by Novo Nordisk. Ozempic is FDA-approved for type 2 diabetes management and cardiovascular risk reduction. Wegovy is FDA-approved specifically for chronic weight management in adults with obesity or overweight with at least one weight-related health condition. The key difference is maximum dose: Ozempic goes up to 2mg weekly, Wegovy goes up to 2.4mg weekly. Clinical trials show Wegovy produces average weight loss of approximately 15% of body weight over 68 weeks at peak dose.

Why Ozempic is frequently prescribed off-label for weight loss

Ozempic is commonly prescribed off-label for weight loss in patients who do not qualify for or cannot access Wegovy. The mechanism is identical and the weight loss outcomes at comparable doses are similar. At 1mg weekly, Ozempic produces approximately 10 to 12% body weight reduction in clinical trials. The distinction is regulatory, not pharmacological.

Mounjaro and Zepbound: the tirzepatide comparison

Mounjaro and Zepbound contain tirzepatide, a dual GIP and GLP-1 receptor agonist manufactured by Eli Lilly. Tirzepatide activates two hormone pathways rather than one, which clinical trials show produces greater average weight loss than semaglutide alone, approximately 20 to 22% of body weight versus 15% for semaglutide at peak doses. The SURMOUNT-1 trial showed 22.5% average weight loss at the highest tirzepatide dose. The nutritional consequences of tirzepatide are similar to semaglutide: reduced food intake, micronutrient depletion, gut disruption, and lean mass loss.

What is consistent across all GLP-1 medications

Regardless of whether you are on Ozempic, Wegovy, Mounjaro, or Zepbound, the nutritional consequences of significantly reduced food intake are the same. Research published in Obesity Reviews in 2026 confirmed that caloric intake drops 16 to 39% across GLP-1 treatments. Micronutrient depletion, electrolyte loss, gut microbiome disruption, lean mass loss, hair loss, sleep disruption, and fatigue are not specific to one medication. They are consequences of the reduced caloric intake all these medications create.

The TAKE approach

TAKE Essentials are formulated for people on any GLP-1 medication, semaglutide or tirzepatide, because the nutritional gaps they create are consistent across the class. View The Eight Essentials. Not sure where to start? Visit the GLP-1 Resource Center.

These statements have not been evaluated by the Food and Drug Administration. TAKE products are not intended to diagnose, treat, cure, or prevent any disease. Always consult your healthcare provider about which GLP-1 medication is right for you.